Triangle specialty pharmaceutical company developing nanoparticle drug products through the NanoCont continuous-manufacturing platform; pipeline reformulates approved small molecules via the 505(b)(2) pathway.
At a glance
- Founded: 2015
- HQ: Durham
- Sector: Biotech
See the full company record.
Founders, funding history and recent signals. Free accounts open immediately.
Sourced company notes 3 topics
Notes on MAA Laboratories · last checked Oct 1, 2026
Overview
Founded 2015 by Dr. Anjani Jha. Headquartered at 400 Park Offices Dr, Suite 214, Durham (Frontier RTP). The NanoCont continuous-manufacturing platform is recognized by the FDA Emerging Technology Program and patented in the U.S. and additional global markets.
Pipeline
Methotrexate nanoparticle tablets (autoimmune and oncology, 505(b)(2)), nintedanib esylate nanoparticle tablets (idiopathic pulmonary fibrosis and progressive fibrotic lung disease, 505(b)(2)), and dasatinib nanoparticle tablets (CML and ALL, 505(b)(2)). Clinical strategies for all three lead programs reviewed and accepted by the FDA; regulatory engagement also with Health Canada and the EU.
Team
Anjani Jha: PhD Pennsylvania State University, postdoc at the MIT-Novartis Center for Continuous Manufacturing, undergraduate at IIT Kharagpur. Senior leadership includes Surya Namburi (regulatory head; prior Biocon, Apotex, Eisai, Torrent, Ranbaxy) and Eric Wesoloski (VP quality and compliance; prior Mylan, Sanofi Pasteur, Takeda, Piramal, AmerisourceBergen). Scientific advisors: Dr. Tage Honoré (ex-Novartis, ex-Novo Nordisk) and Dr. Shankar Hariharan (founder and CEO of Scientiure; ex-Amneal, ex-Forest, ex-Par).
Listed roles
All Triangle rolesChecking listed roles…